Anxiety
17GAD, stress-related anxiety and relief without sedation are extrapolated claims.
Mind & sleep
Adalank
Modified Selank analogue
Community reportsAnxiety · focus7
No FDA-approved product identified for this exact research entry in the targeted review.
What does it do?
N-acetyl Selank amidate is discussed for anxiety and cognition. Cited Selank studies do not establish Adalank efficacy.
Approved & studied uses
No established medical use is documented for this formulation.
Evidence limits
View research →No controlled human Adalank study was verified in the targeted search.6
5 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Evidence limitation
Parent-compound findings cannot establish modified-product safety.6
No FDA-approved product identified for this exact research entry in the targeted review.
Amino-acid sequence
- Thr
- Lys
- Pro
- Arg
- Pro
- Gly
- Pro
7 residues · N → C17
Reference identity · not independently confirmed17
Length7 amino acids (with modifications)
Molecular weight · Da792.93 Da (N-Acetyl form)
Formula, sequence notation & identity
Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2 (N-Acetylated and C-terminal amidated)Identity reported by Pep-Pedia; exact-product sequence and modifications have not been independently confirmed.
Modified Selank analogue
The exact formulation, clinical benefits and long-term safety require further verification.
Pep-Pedia identity details
7 amino acids (with modifications) · 792.93 Da (N-Acetyl form)
Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2 (N-Acetylated and C-terminal amidated)Reference description; checked chemical identity above takes precedence when available.17
Pharmacokinetics
How long does it stay in the body?
Reported half-lifeHuman half-life not verified7
No numerical human elimination estimate was verified for the exact material in this review.
No numerical estimate was found in the checked data or Pep-Pedia profile. A curve would require an unsupported assumption.
What to expect
Study outcomes
Cited parent research does not test Adalank
No controlled human Adalank study was verified in the targeted search.6
Reported timelines
Reference & communityReference timeline; Selank extrapolation
Hours 1–6: clarity; days 1–3: 40% rapid anxiety response; weeks 1–2: gradual relief; 2–4: cognition/mood; 4+: sustained claims; roughly one week post-treatment persistence. None validated for Adalank.17
These are reported timelines, not a prediction of your response.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
Number of responses to this question: not disclosed.
Age range
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 5 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 5 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
Number of responses to this question: not disclosed.
Dosage frequency
Number of responses to this question: not disclosed.
Would recommend
Number of responses to this question: not disclosed.
How discovered
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “320 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Source corrections
Source route labeled Oral describes intranasal administration. Russia-related approval claims refer to Selank.
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQ | 200-300 mcg | 1x daily (morning) | Anxiety reductionReference report | 2-4 weeks | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source route labeled Oral describes intranasal administration. Russia-related approval claims refer to Selank. Source tabs Injectable | |||||
| SubQ | 200-500 mcg | 1x daily | Cognitive enhancementReference report | 2-4 weeks | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source route labeled Oral describes intranasal administration. Russia-related approval claims refer to Selank. Source tabs Injectable | |||||
| SubQ | 200-300 mcg | 2x daily (morning, afternoon) | Stress managementReference report | 2-4 weeks | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source route labeled Oral describes intranasal administration. Russia-related approval claims refer to Selank. Source tabs Injectable | |||||
| SubQ | 100-200 mcg | 1x daily | Initial assessment/trialReference report | 2-4 weeks | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source route labeled Oral describes intranasal administration. Russia-related approval claims refer to Selank. Source tabs Injectable | |||||
| IntranasalNasal spray | 200-300 mcg per dose | 2-3x daily (total 600-900 mcg) | Anxiety managementReference report | 2-4 weeks (14 days in clinical trials) | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source route tab: Oral. Source route labeled Oral describes intranasal administration. Russia-related approval claims refer to Selank. Source tabs Oral | |||||
| IntranasalNasal spray | 300 mcg per dose | 2-3x daily | Cognitive enhancementReference report | 2-4 weeks (14 days in clinical trials) | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source route tab: Oral. Source route labeled Oral describes intranasal administration. Russia-related approval claims refer to Selank. Source tabs Oral | |||||
| IntranasalNasal spray | 200-300 mcg per dose | 2-3x daily at regular intervals | Stress managementReference report | 2-4 weeks (14 days in clinical trials) | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source route tab: Oral. Source route labeled Oral describes intranasal administration. Russia-related approval claims refer to Selank. Source tabs Oral | |||||
| IntranasalNasal spray | 150-200 mcg per dose | 2x daily | Initial trialReference report | 2-4 weeks (14 days in clinical trials) | 17 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source route tab: Oral. Source route labeled Oral describes intranasal administration. Russia-related approval claims refer to Selank. Source tabs Oral | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 2-4 weeks
- Break
- 1-2 weeks minimum to prevent tolerance
Reported timing
Morning preferred, second dose early afternoon if needed
Intranasal
- Use period
- 2-4 weeks (14 days in clinical trials)
- Break
- 1-3 weeks minimum between cycles
Reported timing
Morning, midday, and optionally afternoon at regular intervals
Source tab: Oral. Route follows the actual protocol.
Side effects & safety
Evidence limitation
Parent-compound findings cannot establish modified-product safety.
6Evidence limitation
Human exposure, metabolism and interactions of this exact analogue remain unverified.
6Unknown safety
No direct clinical safety established; dependency-free and enhanced-stability claims are unverified.
Symptoms
Headache, depression, sedation, fatigue, neurological changes, GI distress, nasal bleeding/irritation or injection infection need assessment.
Pregnancy
Pregnancy/lactation safety unstudied.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
5 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Diazepam
Caution reportedParent Selank enhanced diazepam effects in stressed rats; Adalank combination safety is unknown.17
Reference report · Pep-Pedia label: SynergisticSelank
Related compoundModified Selank analogue; longer-persistence claims are unverified.17
Reference report · Pep-Pedia label: SimilarSemax
Unverified pairingReported anxiety/cognition pairing; no human combination trial verified.17
Reference report · Pep-Pedia label: CompatibleBPC-157
Unverified pairingReported anxiety/tissue-repair pairing; compatibility unestablished.17
Reference report · Pep-Pedia label: CompatibleOther medicines or peptides
Not establishedNo exact-product human interaction study was verified; lack of evidence is not evidence of safety.7
Research contextNo matching interactions. Try another name or filter.
Reconstitution
No product-specific preparation or stability instruction was verified. A dilution calculation does not establish suitability for injection.7
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia describes preparation for this route; product-specific stability has not been independently verified.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- Source temperature: 2-8°C. · Reported post-preparation interval: 14-30 days.
The source describes gentle mixing and avoiding vigorous shaking.
Intranasal
Pep-Pedia describes preparation for this route; product-specific stability has not been independently verified.
- Form
- Source describes a prepared product
- Reported parameters
- Source temperature: 2-8°C. · Reported post-preparation interval: 14-30 days.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite, Fluffy PowderReported appearanceClear Solution After ReconstitutionReported appearanceProper LabelingReported variationSlight CompactionReported concernDiscoloration or YellowingReported concernCloudy After Reconstitution
17Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Research findings
No human data verifiedSource context
Source route labeled Oral describes intranasal administration. Russia-related approval claims refer to Selank.
Compound identity & other names
Adalank is marketed as an acetylated, amidated Selank analogue. Parent Selank studies do not establish this modified product’s effects, pharmacokinetics or safety.
Other names: N-acetyl Selank amidate · NA Selank amidate
No FDA-approved product identified for this exact research entry in the targeted review.
How it may work
Proposed GABA, serotonin, BDNF and immune pathways largely derive from Selank; enhanced brain penetration is unverified.17
Cited parent research does not test Adalank
The checked cell paper used Selank, with no significant transcript changes from Selank alone. It provides no direct evidence for acetylated, amidated Adalank.
6Source checks & newer research
Selank in generalized anxiety and neurasthenia
Selank (30 patients) was compared with medazepam (32) in GAD/neurasthenia; the abstract reports similar anxiolysis. This is not Adalank research.
Human comparative study; parent compound Selank; abstract checked18Selank in ethanol-exposed rats
Selank prevented ethanol-related memory/attention impairment in rats after intraperitoneal treatment. The source page incorrectly describes this paper as intranasal BDNF research.
Rat experiment; parent compound Selank; PubMed abstract checked19Selank plus diazepam in stressed rats
Combined Selank/diazepam improved anxiety measures under chronic mild stress in rats. This does not establish Adalank interactions or a safe human combination.
Rat experiment; full text checked20Selank in human neuroblastoma cells
Selank alone did not change measured GABAergic gene-expression levels in IMR-32 cells; combinations altered responses. No Adalank or clinical efficacy was tested.
Human neuroblastoma cell culture; full text checked21Research areas and evidence gaps
- No controlled human Adalank study was verified in the targeted search.
- A product-specific research-vial quantity was not independently verified in this review.
Community reports Unvalidated
Pep-Pedia discusses anxiety and cognitive interest.7
Editorial summary, not a measured community survey, clinical protocol or recommendation.
Search coverage and review status
No exact-compound clinical paper was verified. Checked parent-Selank cell evidence is explicitly separated from Adalank.
- Checked
- 2026-10-12
- Search
- "Adalank" "N-acetyl Selank amidate" clinical study 2025 2026
- Catalog
- Pep-Pedia ↗ · 14 listed references retained
- Targeted search and selected primary-source checks, not an exhaustive systematic review.
- Preserved bibliography entries marked unreviewed have not had their findings independently verified.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1Selank and GABAergic Neurotransmission Gene Expression (Parent Compound)Primary source checked
AI-PREPARED SUMMARY
This cell experiment tested parent Selank, not Adalank. Selank alone did not change the tested transcript levels; combined exposures changed gene-expression responses.
Pep-Pedia bibliography · Checked 2026-10-12
2Selank for Generalized Anxiety Disorder - Non-inferiority Trial (Parent Compound)Abstract checked
AI-PREPARED SUMMARY
A 62-patient active-comparator study reported similar anxiolysis to medazepam. The English abstract lacks numerical effect sizes and detailed dosing.
Pep-Pedia bibliography · Checked 2026-10-12
3Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurastheniaAbstract checked
AI-PREPARED SUMMARY
A 62-patient active-comparator study reported similar anxiolysis to medazepam. The English abstract lacks numerical effect sizes and detailed dosing.
Pep-Pedia bibliography · Checked 2026-10-12
4GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 CellsPrimary source checked
AI-PREPARED SUMMARY
This cell experiment tested parent Selank, not Adalank. Selank alone did not change the tested transcript levels; combined exposures changed gene-expression responses.
Pep-Pedia bibliography · Checked 2026-10-12
5Optimization of the treatment of anxiety disorders with selankAbstract checked
AI-PREPARED SUMMARY
Compared phenazepam alone in 30 patients with phenazepam plus Selank in 40; reported earlier symptom change and fewer benzodiazepine adverse effects. Abstract omits dosing details.
Pep-Pedia bibliography · Checked 2026-10-12
6GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 CellsPrimary source checked
AI-PREPARED SUMMARY
This cell experiment tested parent Selank, not Adalank. Selank alone did not change the tested transcript levels; combined exposures changed gene-expression responses.
Cited parent research does not test Adalank
The checked cell paper used Selank, with no significant transcript changes from Selank alone. It provides no direct evidence for acetylated, amidated Adalank.
Additional research · Checked 2026-10-12
7Pep-Pedia: AdalankCommunity source checked
AI-PREPARED SUMMARY
Secondary editorial profile and reported practices; not clinical validation.
8Selank in ethanol-exposed ratsAbstract checked
AI-PREPARED SUMMARY
Selank prevented ethanol-related memory/attention impairment in rats after intraperitoneal treatment. The source page incorrectly describes this paper as intranasal BDNF research.
Pep-Pedia bibliography; reconciled with an existing checked primary-source record · Checked 2026-10-12
9Selank plus diazepam in stressed ratsPrimary source checked
AI-PREPARED SUMMARY
Combined Selank/diazepam improved anxiety measures under chronic mild stress in rats. This does not establish Adalank interactions or a safe human combination.
Pep-Pedia bibliography; reconciled with an existing checked primary-source record · Checked 2026-10-12
10Tuftsin Analog Selank and Inflammation-Related Gene Expression (Parent Compound)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Parent Selank was associated with changes in 34 inflammatory-gene transcripts; the experiment does not test Adalank.
Reported population / model
Mice
Reported study details
100 mcg/kg i.p. · Gene expression analysis at 6 and 24 hours
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
11Immunomodulatory Effects of Selank in Anxiety Patients (Parent Compound)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Th1/Th2 cytokine measures changed during Selank treatment in people with GAD or neurasthenia; Adalank was not tested.
Reported population / model
Humans
Reported study details
14 days treatment · Cytokine balance measured
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
12Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in RatsLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
13Selank plus diazepam in stressed ratsPrimary source checked
AI-PREPARED SUMMARY
Combined Selank/diazepam improved anxiety measures under chronic mild stress in rats. This does not establish Adalank interactions or a safe human combination.
Pep-Pedia bibliography; reconciled with an existing checked primary-source record · Checked 2026-10-12
14The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank actionPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Parent Selank was associated with changes in 34 inflammatory-gene transcripts; the experiment does not test Adalank.
Reported population / model
Mice
Reported study details
100 mcg/kg i.p. · Gene expression analysis at 6 and 24 hours
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
15Expression of inflammation-related genes in mouse spleen under tuftsin analog SelankPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Parent Selank was associated with changes in 34 inflammatory-gene transcripts; the experiment does not test Adalank.
Reported population / model
Mice
Reported study details
100 mcg/kg i.p. · Gene expression analysis at 6 and 24 hours
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
16Immunomodulatory effects of selank in patients with anxiety-asthenic disordersPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Th1/Th2 cytokine measures changed during Selank treatment in people with GAD or neurasthenia; Adalank was not tested.
Reported population / model
Humans
Reported study details
14 days treatment · Cytokine balance measured
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
17Pep-Pedia: Adalank — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12
18Selank in generalized anxiety and neurastheniaAbstract checked
AI-PREPARED SUMMARY
Selank (30 patients) was compared with medazepam (32) in GAD/neurasthenia; the abstract reports similar anxiolysis. This is not Adalank research.
Selank in generalized anxiety and neurasthenia
Selank (30 patients) was compared with medazepam (32) in GAD/neurasthenia; the abstract reports similar anxiolysis. This is not Adalank research.
Additional primary-source check · Checked 2026-10-12
19Selank in ethanol-exposed ratsAbstract checked
AI-PREPARED SUMMARY
Selank prevented ethanol-related memory/attention impairment in rats after intraperitoneal treatment. The source page incorrectly describes this paper as intranasal BDNF research.
Selank in ethanol-exposed rats
Selank prevented ethanol-related memory/attention impairment in rats after intraperitoneal treatment. The source page incorrectly describes this paper as intranasal BDNF research.
Additional primary-source check · Checked 2026-10-12
20Selank plus diazepam in stressed ratsPrimary source checked
AI-PREPARED SUMMARY
Combined Selank/diazepam improved anxiety measures under chronic mild stress in rats. This does not establish Adalank interactions or a safe human combination.
Selank plus diazepam in stressed rats
Combined Selank/diazepam improved anxiety measures under chronic mild stress in rats. This does not establish Adalank interactions or a safe human combination.
Additional primary-source check · Checked 2026-10-12
21Selank in human neuroblastoma cellsPrimary source checked
AI-PREPARED SUMMARY
Selank alone did not change measured GABAergic gene-expression levels in IMR-32 cells; combinations altered responses. No Adalank or clinical efficacy was tested.
Selank in human neuroblastoma cells
Selank alone did not change measured GABAergic gene-expression levels in IMR-32 cells; combinations altered responses. No Adalank or clinical efficacy was tested.
Additional primary-source check · Checked 2026-10-12